Merck Free Cash Flow 2012-2026 | MRK
Merck annual/quarterly free cash flow history and growth rate from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Merck free cash flow for the quarter ending March 31, 2026 was 10,536.00, a year-over-year.
- Merck free cash flow for the twelve months ending March 31, 2026 was , a year-over-year.
- Merck annual free cash flow for 2024 was $18.096B, a 97.92% increase from 2023.
- Merck annual free cash flow for 2023 was $9.143B, a 37.83% decline from 2022.
- Merck annual free cash flow for 2022 was $14.707B, a 69.55% increase from 2021.
| Merck Annual Free Cash Flow | |
|---|---|
| 2024 | 18,096.00 |
| 2023 | 9,143.00 |
| 2022 | 14,707.00 |
| 2021 | 8,674.00 |
| 2020 | 3,188.00 |
| 2019 | 5,515.00 |
| 2018 | 8,307.00 |
| 2017 | 4,563.00 |
| 2016 | 8,762.00 |
| 2015 | 11,255.00 |
| 2014 | 6,672.00 |
| 2013 | 10,106.00 |
| 2012 | 8,068.00 |
| 2011 | 10,660.00 |
| Merck Quarterly Free Cash Flow | |
|---|---|
| 2025-09-30 | 10,536.00 |
| 2025-06-30 | 3,701.00 |
| 2025-03-31 | 1,172.00 |
| 2024-12-31 | 18,096.00 |
| 2024-09-30 | 15,583.00 |
| 2024-06-30 | 7,075.00 |
| 2024-03-31 | 2,229.00 |
| 2023-12-31 | 9,143.00 |
| 2023-09-30 | 9,886.00 |
| 2023-06-30 | 3,071.00 |
| 2023-03-31 | 332.00 |
| 2022-12-31 | 14,707.00 |
| 2022-09-30 | 11,426.00 |
| 2022-06-30 | 6,950.00 |
| 2022-03-31 | 3,777.00 |
| 2021-12-31 | 8,674.00 |
| 2021-09-30 | 4,787.00 |
| 2021-06-30 | 1,162.00 |
| 2021-03-31 | 158.00 |
| 2020-12-31 | 3,188.00 |
| 2020-09-30 | 1,209.00 |
| 2020-06-30 | 1,072.00 |
| 2020-03-31 | -279.00 |
| 2019-12-31 | 5,515.00 |
| 2019-09-30 | 6,310.00 |
| 2019-06-30 | 3,043.00 |
| 2019-03-31 | 741.00 |
| 2018-12-31 | 8,307.00 |
| 2018-09-30 | 5,644.00 |
| 2018-06-30 | 3,504.00 |
| 2018-03-31 | 705.00 |
| 2017-12-31 | 4,563.00 |
| 2017-09-30 | 1,259.00 |
| 2017-06-30 | 2,871.00 |
| 2017-03-31 | -53.00 |
| 2016-12-31 | 8,762.00 |
| 2016-09-30 | 5,681.00 |
| 2016-06-30 | 3,119.00 |
| 2016-03-31 | 1,894.00 |
| 2015-12-31 | 11,255.00 |
| 2015-09-30 | 7,502.00 |
| 2015-06-30 | 4,507.00 |
| 2015-03-31 | 2,081.00 |
| 2014-12-31 | 6,672.00 |
| 2014-09-30 | 8,197.00 |
| 2014-06-30 | 4,169.00 |
| 2014-03-31 | 2,156.00 |
| 2013-12-31 | 10,106.00 |
| 2013-09-30 | 7,509.00 |
| 2013-06-30 | 3,915.00 |
| 2013-03-31 | 1,990.00 |
| 2012-12-31 | 8,068.00 |
| 2012-09-30 | 7,037.00 |
| 2012-06-30 | 4,312.00 |
| 2012-03-31 | 1,823.00 |
| 2011-12-31 | 10,660.00 |
| 2011-09-30 | 8,030.00 |
| 2011-06-30 | 3,884.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |